医院2012年至2016年保肝药物临床应用分析

摘要

Objective To understand the application and development trend of liver-protecting drugs for patients in our hospital from 2012 to 2016, and provide clinical references for the rational drug use. Methods The consumption sum, DDDs and DDC of liver-protecting drugs were retrospectively analyzed by means of defined daily dose recommended by WHO. Results The top 10 liver-protecting drugs in the list of consumption sum and DDDs were Magnesium Isoglycyrrhizinate Injection, Reduced Glutathione for Injection, Ademetionine 1, 4-Butanedisulfonate for Injection, Reduced Glutathione Tablets, Polyene Phosphatidylcholine Injection, Ursodeoxycholic Acid Capsules, BicycloI Tablets and Compound Glycyrrhizin Tablets. The DDC of Magnesium Isoglycyrrhizinate Injection, Ornithine Aspartate Injection, Ademetionine 1, 4-Butanedisulfonate for Injection, Kuhuang Injection, and Hepatocyte Growth-Promoting Factors Injection remained high. Conclusion The application of liver-protecting drugs in our hospital is relatively reasonable, which is in accordance with the medication principles of safety, effective and economic.%目的 了解2012年至2016年医院患者保肝药物应用情况,分析其发展趋势,为临床合理应用提供参考.方法 采用世界卫生组织推荐的限定日剂量分析方法,回顾性统计并分析医院2012年至2016年保肝药总销售金额、用药频度(DDDs)、限定日费用(DDC).结果 销售金额和用药频度均位于前10位的保肝药物分别为异甘草酸镁注射液、注射用还原型谷胱甘肽、注射用丁二磺酸腺苷蛋氨酸、谷胱甘肽片、多烯磷脂酰胆碱注射液、熊去氧胆酸胶囊、双环醇片、复方甘草酸苷片.异甘草酸镁注射液、门冬氨酸鸟氨酸注射液、注射用丁二磺酸腺苷蛋氨酸、苦黄注射液、促肝细胞生长素的DDC居高不下.结论 医院保肝药物应用相对合理,符合安全、有效、经济的用药原则.